Drug Trial Radar · NCT07397611
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Mar 9, 2026
Primary completion
Jan 31, 2028
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Arcus Biosciences, Inc.
- First posted
- Feb 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type of HIF-2α inhibitor) * Zimberelimab (a type of monoclonal antibody)
Conditions
- Renal Cell Carcinoma
- Kidney Cancer
- Kidney Neoplasm
- Renal Carcinoma
Interventions
CasdatifanDrug
HIF-2α inhibitor, tablet taken orally per protocol.
ZimberelimabDrug
monoclonal antibody, multi-dose vial, via intravenous (through the vein) infusion, per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tumor Size Reduction RateTime frame: Disease assessment will occur at pre-surgery visit week 11 ± 2 weeks.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Not yet recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.